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Single-photon emission computed tomography
Introduction: Platelets play amajor role in thrombo-embolic diseases, notably by forming a thrombus that can ul-
timately occlude a vessel. Thismay provoke ischemic pathologies such asmyocardial infarction, stroke or periph-
eral artery diseases, which represent themajor causes of deathworldwide. The aim of this study was to evaluate
the speciﬁcity of radiolabeled Rat-Anti-Mouse antibody (RAM.1).
Methods: We describe a method to detect platelets by using a RAM.1 coupled with the chelating agent
hydrazinonicotinic acid (HYNIC) conjugated to 99mTc, for Single Photon Emission Computed Tomography
(SPECT). To induce platelet accumulation at a site of interest, we used a mouse model of FeCl3 induced injury
of the carotid artery. 90 min after i.v. injection of [99mTc][Tc(HYNIC)-RAM.1], biodistribution of the radiolabeled
RAM.1was assessed, SPECT imaging and histological analysis were performed on themice that underwent FeCl3-
induced vessel damage.
Results:Wedemonstrated a quick and strong afﬁnity of the radiolabeled RAM.1 for the platelet thrombus. Results
clearly demonstrated the ability of this radioimmunoconjugate for detecting thrombi from 10min post injection
with an exceptional thrombi uptake. Using FeCl3, the median ratio between the thrombus and the background
was 12.4 (range 9.3–42.3) as compared to 1.0 (range: 0.86–2.7) p b 0.05 when using 0.9% NaCl.
Conclusion: Thanks to the high sensitivity of SPECT, we provided evidence that [99mTc][Tc(HYNIC)-RAM.1] repre-
sents a powerful tool to detect localized platelet thrombi which could potentially be used in humans. Because of
the relative low cost and high sensitivity, these results encourage further study like the detection of non-induced
thrombus and further developments toward clinical application. This is further supported by the fact that RAM.1
recognizes human platelets.
© 2018 Elsevier Inc. All rights reserved.1. Introduction
Blood platelets are small anucleated cells that circulate freely in the
bloodstream. They play a key role in hemostasis, which represents the
physiological process leading to the arrest of bleeding. After a vessel
wall injury, platelets adhere to the adhesive proteins exposed to the
ﬂowing blood, become activated and aggregate to form a plug that
seals the breach [1]. The same responses can occur in a diseased artery
presenting a stenosed atherosclerotic plaque. Erosion or rupture of
such a plaque exposes thrombogenic materials leading to the recruit-
ment of circulating platelets, which form a thrombus that can ultimately
occlude the vessel. Such a phenomenon, called arterial thrombosis, re-
sults in life-threatening ischemic pathologies such as stroke and myo-
cardial infarction which are leading causes of death worldwide [2].C, 23 rue du Loess, CNRS, UMRThrombosis is not exclusively an acute phenomenon but can occur re-
peatedly on a developing atherosclerotic plaque or in a vessel aneurysm,
while being clinically silent [3]. Detection of such thrombotic events
might be useful to clinicians to adapt therapeutic approaches
preventing thrombo-embolic complications.
Because of the central role of platelets in thrombus formation, they
represent a privileged target for thrombus imaging. Therefore, the de-
tection of platelet accumulation is ofmajor importance to detect throm-
botic pathologies. Many strategies such as ultrasound, magnetic
resonance imaging (MRI) or nuclear imaging techniques [4]were devel-
oped to image thrombus clinically and pre-clinically. McCarty and col-
leagues [5] proposed an indirect strategy based on ultrasound imaging
allowing detection of activated VonWillebrand factor (VWF) following
the injection of GPIb-coatedmicrobubbles. Such an approachwould not
only detect VWF on activated platelets within thrombi, but also
immobilized VWF on the vascular endothelium and therefore provide
a non-invasive approach to image advanced prothrombotic and inﬂam-
matory phenotype in atherosclerotic disease. Several probes were
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factor XIII bymolecularMRI [6–8]. One drawback of MRI is the low sen-
sitivity of contrast agent detection compared to nuclear techniques. In-
deed, nuclear imaging techniques such as positron emission
tomography (PET) and single photon emission computed tomography
(SPECT) provide excellent sensitivity allowing detection in the
picomolar range. Recently the targeting of 99mTc radiolabeled fucoidan
in rats allowing in vivo detection of P-selectin, such as an arterial throm-
bus has been evaluated [9]. Sequentialwhole-body acquisitions showed
an early renal uptake of the tracer, followed by the bladder, with a high
activity in urine, indicating a renal elimination of radiolabeled hydro-
philic LMW fucoidan. Another study reported the use of an 111In
radiolabeled single-chain antibody targeting the LIBS epitope of acti-
vated integrin αIIbβ3, to selectively reveal platelet activation, and
wall-adherent non-occlusive thrombosis in a mouse model [10].
Bitistatin, a single-chain disintegrin labeled with 123I has also been
used to locate thrombi and emboli by scintigraphic imaging [11]. Finally,
monoclonal antibodies and small antibody fragmentswere radiolabeled
and used for the sensitive detection of activated platelets and thrombo-
sis [12]. In any cases, the ratio of radioactivitymeasured between the in-
jury site containing the platelets and the surrounding tissue was
modest. A ratio between 2 and 6 is not sufﬁcient to clearly delineate a
thrombosis.
In the present study, we proposed to use RAM.1, a rat monoclonal
antibody reacting against mouse and human GPIbβ, a subunit of the
GPIb-V-IX complex [13], and that was generated in our laboratory.
This antibody was labeled with 99mTc to image thrombi in vivo. This
complex is highly speciﬁc for platelets suggesting that such a strategy
will detect non-moving platelets notably those present in a thrombus
or in an aneurysm. RAM.1 is a particularly interesting antibody since it
efﬁciently and speciﬁcally labels platelets as observed in immunoﬂuo-
rescence studies [1]. Moreover, it has already been used in vivo, in
mice, and presented the potential to bind the human GPIb-V-IX com-
plex [14].
We radiolabeled RAM.1with 99mTc (T1/2 = 6 h) by conjugationwith
the chelating agent hydrazinonicotinic acid (HYNIC) to perform single
photon emission SPECT imaging in mice. S-HYNIC, as developed by
Abrams and coworkers [15], appears to be an ideal Bifunctional Chelat-
ingAgent (BCA) for 99mTc-labeling, due to its rapid and efﬁcient labeling
of antibodies. This approach consists of a conjugation step and a labeling
step. In the conjugation step, S-HYNIC reacts with ε-amino groups of ly-
sine residues in the antibody, resulting in a HYNIC-antibody conjugate.
Conjugation of HYNIC to the antibody and optimal conditions (concen-
tration of antibody, buffer solution and time) for radiolabeling the
immuno-conjugate were determined, and the reactivity of the
immunoconjugate to platelets was assessed by ﬂow cytometry analysis.
Formation of a platelet thrombus was achieved by using a well charac-
terized FeCl3-injury model of the mouse carotid artery [16]. Selective
uptake of [99mTc][Tc(HYNIC)-RAM.1] in the thrombus of injured carotid
artery was demonstrated by SPECT imaging.
2. Materials and methods
2.1. RAM.1 production and puriﬁcation
P3.×63.Ag8.653 hybridoma cells expressing RAM.1were generated as
earlier described [13]. These cells were cultured in a RPMI 1640 medium
containing 10% of FBS and 1% PSG. The supernatant of the culturewas col-
lected every 2–3 days and kept at 4 °C. Once a signiﬁcant amount of su-
pernatant was obtained, RAM.1 was puriﬁed by using a Prot G Hitrap
column (GE Heathcare Lifescience, Pittsburgh, PA) as described earlier.
2.2. Conjugation of HYNIC to RAM.1
Two different buffer solutions were explored (1 M NaHCO3 pH 8.2
and 0.1 M Borate buffer pH 8.5) to assess the effect of conjugation onlabeling efﬁciency. Three different antibody concentrations were used
(0.5 mg/mL, 8.7 mg/mL and 14 mg/mL). The reaction time was varied
from 30 min to 120 min. Similar results were obtained when varying
buffer solution and time reaction. Themost important factorwas the an-
tibody concentration. At the lowest antibody concentration, virtually no
HYNIC was conjugated to the antibody, and labeling efﬁciencies were
therefore very low. More efﬁcient conjugation and subsequent labeling
was obtained at higher concentrations (8.7 mg/mL). Conjugation reac-
tion failed when increasing antibody concentration (14 mg/mL). Opti-
mum conjugation was obtained by incubating RAM.1 with S-HYNIC
for 2 h in darkness using a 20:1 HYNIC/RAM.1 M ratio. These conjuga-
tion conditions (borate buffer, HYNIC/RAM.1 20:1, 2 h incubation
time) were used for all further in vitro and in vivo experiments.
The monoclonal antibody RAM.1 was generated in our laboratory
[13] and the rat IgG isotype controlwas obtained fromBectonDickinson
(Le Pont de Claix, France). RAM.1 monoclonal antibodies were
radiolabeled with 99mTc after bioconjugation with S-Hynic
(succinimidylhydrazinonicotinamide, SynChem, Inc.). 320 μL of borate
buffer (0.1 mol/L, pH 8.5) and 17 μL of a 1 mg/mL solution of S-Hynic
in dimethylformamide (DMF) were added to a solution of RAM.1
(435 μg in 50 μL of phosphate buffer). Protected from light, the solution
was stirred at room temperature for 2 h. A sodiumcitrate buffer solution
(200 μL, 0.01 mol/L, pH 5.2) was added and the resulting solution was
centrifuged at 13,000 RPM over 30,000 MW cutoff ﬁltering devices
(Amicon Ultra 0.5 mL centrifugal ﬁlters, Millipore).
The HYNIC conjugated RAM.1 antibodies were collected with 4 fold
75 μL of sodium citrate (0.01 mol/L, pH 5.2) and stored at 5 °C. An ali-
quot (20 μL) of this mother solution was used to determine the RAM.1
concentration (380 μg/mL) and to assess its afﬁnity for platelets before
radiolabeling.
2.3. Radiolabeling with 99mTc
6 μL of a freshly prepared hydrochloric (0.1 mol/L) solution of SnCl2
(40 mg/mL) was added to 5 mL of an aqueous solution of tricine (36
mg/mL, Sigma-Aldrich Co, adjusted to pH 7.1 with NaOH 1 mol/L).
120 μL of this solution was transferred into a 2 mL eppendorf tube and
208 MBq (80 μL) of freshly eluted sodium pertechnetate (Na99mTcO4)
was added. Technetium-99 m, as [99mTcO4]Na in physiological solution,
was obtained from a 99Mo/99mTc generator Elumatic® III (CisBio/IBA
Molecular, France). The solutionwas allowed to react 10min, before ad-
dition of 90 μL of the HYNIC conjugated RAM.1 solution (380 μg/mL)
and 110 μL of NaCl (0.9%). After 15 min of reaction, the solution was di-
luted with 400 μL of NaCl (0.9%) and puriﬁed by centrifugation over
30,000 MW cutoff ﬁlters (Amicon Ultra 0.5 mL centrifugal ﬁlters pre-
treated with 40 μL of 0.9% NaCl) in order to remove the excess of free
99mTc-pertechnetate and uncoupled 99mTc-Tricine.
The radiolabeled antibody (77 MBq) solution was diluted in 300 μL
of NaCl (0.9%). The resulting solution was used to prepare calibrated
dose (10 MBq± 1 in 100 μL of 0.9% sterile NaCl) for in vivo imaging.
The radiochemical purity was determined by thin-layer chromatog-
raphy (Sigma-Aldrich, France) with 0.1 mol/L citrate buffer (pH 5.0) as
the mobile phase phase for determination of the sum of 99mTcO4− and
the radiolabeled tricine (Rf = 1) and with ammonia:ethanol:water in
a ratio of 1:2:5 for colloid determination. In the last phase, colloid re-
mains at the origin, while the 99mTc-HYNIC–RAM.1 and possible impu-
rities such as 99mTcO4− or 99mTc-tricine moves to the top.
2.4. RAM.1 binding to platelets
To evaluate whether HYNIC-coupled RAM.1 is efﬁciently binding to
platelets, washed human platelets prepared as previously described
[17] were incubated with HYNIC-coupled RAM.1, with untreated
RAM.1 (10 μg/mL) or with an IgG control antibody (10 μg/mL) for 10
min, before adding a FITC-conjugated goat-anti-rat antibody (1/100)
for 10 min. Samples were ﬁnally diluted in 500 μL of the same buffer
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Germany). After decay of Tc-99 m, [99gTc]Tc-tricine-HYNIC-labeled
RAM1 was also evaluated with the same manner to check the binding
capability.
2.5. FeCl3-injury thrombosis model
FeCl3 induced thrombosis was performed as described earlier [16].
8-week old mice were anesthetized with an intraperitoneal injection
of ketamine (100mg/kg) and xylazine (20mg/kg). The common carotid
arteries were exposed and vascular injury was induced by applying a
Whatman ﬁlter paper saturated with 7% FeCl3 in 0.9% NaCl (or 0.9%
NaCl for control) to the left carotid artery for 2 min. Mice were assigned
to either the RAM.1 or the control group. Experiments were done in
blocks of 5 animals each. Mice in two groups had vascular injury and
one group received saline as control.
2.6. RAM.1 afﬁnity in vivo
The afﬁnity of RAM.1 in vivowas evaluated by injection of 500 μg of
rabbit IgG (non-speciﬁc antibody) right after the thrombus induction by
FeCl3 (ci below). 30 min later, 10 μg of RAM.1-488 nm were injected.
The mice (n= 5) were perfused with 2.5% glutaraldehyde via cardiac
puncture in the left ventricle using a 5-ml syringe with a 25-gauge nee-
dle. An incision in the right atrium allowed to remove blood, saline, and
ﬁxative. Vessel segments were dissected and were post-ﬁxed in 4%
paraformaldehyde overnight. The carotids were washed in phosphate-
buffered saline, frozen in optimal cutting temperature embedding me-
dium, and cross-sectioned.
2.7. Micro-SPECT/CT data acquisition and image processing
The imaging procedure was initiated immediately after induction of
the thrombosis. 10MBq of 99mTc-RAM.1 in sodium chloride (0.9%, 6 μg
antibodies), pH ~7, were injected through the right jugular vein. Each
dose was measured and recorded before and after injection to deter-
mine the exact injected dose. Micro-SPECT/CT acquisitions were per-
formed using the multimodality imaging system developed in our
institute [18,19]. Mice were placed supine on a bed and kept anesthe-
tized using 1% isoﬂurane throughout the experiment. The bed was
ﬁrst moved in the micro-CT ﬁeld of view (FOV). 360 X-ray projections
were acquired over 360° at 40 kV and 75 μA with a total acquisition
time of 42 s. The 256 × 512 × 720 (0.2 × 0.2 × 0.2 mm) micro-CT vol-
ume was reconstructed using Feldkamp algorithm implemented on
GPU architecture. The mouse was then moved into the micro-SPECT
FOV. Micro-SPECT images were acquired using the four-head gamma
camera equipped with 1-mm pinhole collimators. 128 projections per
camera, each 5 s, were acquired over 360° for each bed position with
an 8 mm axial extent. Three bed positions were required to scan the
neck area of the mouse. The total imaging time (micro-CT and micro-
SPECT)was 38min. Imageswere reconstructed using 3-dimensional or-
dered-subsets expectation maximization algorithm using pre-calcu-
lated system matrix into a 210 × 192 × 90 volume [20]. 20 iterations
and 4 subsets were used for SPECT reconstruction. Fused reconstructed
data were visualized using anatomist [21]. No attenuation and scatter
corrections were performed.
2.8. Ex-vivo biodistribution studies and blood sampling
After thrombus induction (or 0.9% Nacl used as control) and
radiolabeled RAM.1 injection, blood samples were obtained from tail
blood sampling for blood half-life studies or were collected through
left-ventricle puncture for biodistribution studies. The blood samples
were weighted. Mice (n= 5 for each group) were sacriﬁced and dis-
sected 90 min and 240 min after radiolabeled RAM.1 injection. Organs
were also weighted. The radioactivity of the blood and the sampleswere counted on a Wallac 1470 Wizard gamma counter (Perkin
Elmer, Finland). Results are represented as a percentage of injected
dose per gram (%ID/g). The radioactivity of each samplewas normalized
to the amount of radioactivity injected and corrected from the isotope
decay.
2.9. Immunoﬂuorescence analysis of carotid thrombosis
Experimentswere performed as previously published [22]. Themice
(n=5)were perfusedwith 2.5% glutaraldehyde via cardiac puncture in
the left ventricle using a 5-ml syringe with a 25-gauge needle. An inci-
sion in the right atrium allowed to remove blood, saline, and ﬁxative.
Vessel segments were dissected and were post-ﬁxed in 4% paraformal-
dehyde overnight. The carotids were washed in phosphate-buffered sa-
line, frozen in optimal cutting temperature embedding medium, and
cross-sectioned. Cryosections (8 μm) were stained for platelets using a
RAM.1 antibody coupled to Alewa-488 (10 μg/ml). The samples were
also stained with DAPI to detect the endothelium. A LEICA DMI 4000 B
microscope (Leica Microsystem) was employed, with a Leica EL 6000
ﬂuorescencent lamp and a 20×, 0.5 numerical aperture oil objective. Im-
ages were acquired with a Photometrics charge-coupled device (CCD)
camera (CoolSNAP HQ Monochrome, Photometrics, Tucson, AZ, USA)
and analyzed with ImageJ software (National Institute of Health,
Bethesta, MD, USA).
2.10. Data analysis
All group of experiments were performed on 5 mice. The signiﬁ-
cance of results was assessed using an exact non-parametric Mann &
Whitney test (StatXact 7.0, Cytel Inc). Non parametric statistics was
used due to the small number of mice used (p b 0.05).
2.11. Ethicals statement
Care and use of the mice in this study follow the national guidelines
approved by the ethic local committee (CREMEAS), permit No. AL/05/
12/02/13.
3. Results
3.1. Binding properties of 99mTc and Hynic bound RAM.1
To ensure that coupling of Hynic and 99mTc to RAM.1 does not dra-
matically impair the ability of this antibody to bind to platelets, a ﬂow
cytometry approachwas utilized.We observed that HYNIC-RAM.1 incu-
bated with washed human platelets efﬁciently bound to platelets when
compared to a control IgG (Fig. 1). Only a slight reduction in mean ﬂuo-
rescence intensity of HYNIC-RAM.1 was detected as compared to
uncoupled control RAM.1 (Fig. 1). This indicated that coupling to
Hynic and/or 99mTc does not profoundly modify the binding properties
of RAM.1. After decay of Tc-99 m, [99gTc]Tc-tricine-HYNIC-labeled
RAM1 was also evaluated with the same manner to check the binding
capability and showed the same results as with HYNIC-RAM.1.
In vivo, the speciﬁcity of RAM.1 was tested by injection of a non-spe-
ciﬁc antibody (in our case rabbit IgG) at a high dose (50 times the
amount of RAM.1 injected) right after the induction of a thrombus
using FeCl3. RAM.1-488 nm was injected after 30 min; we can observe
that RAM.1 still labeled the thrombus (Fig. 2).
3.2. Biodistribution of [99mTc][Tc(HYNIC)-RAM.1]
Biodistribution of the radiolabeled RAM.1 was assessed 90min and
240 min post-injection. At 90 min after injection, the highest accumula-
tion of radioactivity, expressed as the percentage of injected dose per
gram for different tissues, occurred in the spleen (95%ID/g), (Fig. 3). Sig-
niﬁcant amounts were also detected in the blood (23%ID/g), bladder
Fig. 1. Binding properties of [99mTc][Tc(HYNIC)-RAM.1]. The binding property of [99mTc]
[Tc(HYNIC)-RAM.1] was determined by ﬂow cytometry using washed human platelets
in comparison with unlabeled RAM.1 (10 μg/mL) and a control IgG (10 μg/mL).
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sured in the liver (10%ID/g), heart (6%ID/g) and kidneys (4%ID/g), while
only marginal amounts were detected in the skin, bones, muscles, and
brain (b1%ID/g). At 240 min after injection, the spleen uptake (46%ID/
g) was 50% lower than at 90 min but still much higher than the back-
ground. Besides others organs, the uptake was similar at 90 and 240
min.
3.3. In vivo detection of a forming thrombus by SPECT imaging
SPECT imaging performed around the region of FeCl3-induced vessel
damagewas performed 90 min after i.v. injection of [99mTc][Tc(HYNIC)-
RAM.1]. Analysis of the SPECT/CT images revealed an uptake of the
radiolabeled RAM.1 at the site of injury in all injected mice (n= 5)
(Fig. 4). This result demonstrates that [99mTc][Tc(HYNIC)-RAM.1] la-
beled aggregating platelets can be visualized at the site of lesion, and
underscores the potential of SPECT/CT to allow detection of fresh
thrombus formation in living animals. Interestingly, the uptake was
concentrated at site of vessel injury and we observed only very low
quantity of radioactivity in the adjacent surrounding. These results
highlight the high degree of speciﬁcity of RAM.1 to detect immobilized
platelets versus circulating platelets. To further assess the speciﬁcity of
radiolabeled RAM.1, we performed a control surgical procedure by ap-
plying 0.9% NaCl to the vessel wall instead of FeCl3. No thrombus wasvessel
thrombus
Fig. 2. RAM.1 afﬁnity in vivo. Fluorescence image of RAM.1-488 nm after thrombus
induction by FeCl3 and injection of 500 μg of rabbit IgG (non-speciﬁc anti-body).observed histologically or in SPECT-CT images (data not shown). We
calculated the ratio between the radioactivity measured in the injury
site (with FeCl3 or 0.9% NaCl) over that in the adjacent surrounding
(Fig. 5). Using FeCl3, the median ratio between the thrombus and the
background was 12.4 (range 9.3–42.3) as compared to 1.0 (range:
0.86–2.7) p b 0.05 when using 0.9% NaCl.
3.4. Histology of the thrombus
Histology and electronmicroscopy of FeCl3-induced injury ofmouse
carotid has already been described earlier [16]. Histological analysis was
performed in the mice (n= 5) that underwent CT/SPECT imaging to
show that the increase in radioactivity measured in these animals
corresponded to a thrombus. Bright-ﬁeld images showed that a volumi-
nousmass was found within the lumen of mouse carotid artery (Fig. 6).
Immunoﬂuorescence staining with RAM.1 coupled to Alexa-488, con-
ﬁrmed that this mass was an accumulation of platelets, i.e. a thrombus.
Staining with DAPI to identify the endothelium indicated that the
formed thrombus was intraluminal.
4. Discussion
This study demonstrates a) the ability of this complex to detect a
thrombus in vivo and b) the in vivo high sensitivity of the radioactive
complex.
Platelets are involved in thrombus formation which can lead to life-
threatening ischemic complications such as stroke and myocardial in-
fraction. Thus, the in vivo follow up of platelet accumulation is of impor-
tance in order to non-invasively detect the presence of thrombi. In the
present study, we developed a novel SPECT radiotracer for in vivo imag-
ing. Collecting non-invasively semi-quantitative information on the ex-
pression levels of functional molecules and metabolic activities in vivo
can be accomplished by nuclear imaging techniques such as SPECT pro-
viding a functional diagnosis with high sensitivity and good spatial res-
olution. We chose a nuclear imaging modality for its very high
sensitivity compared to MRI or optical techniques. We used RAM.1, a
monoclonal antibody which is already known to be highly speciﬁc for
platelets and we coupled it to Hynic (hydrazinonicotinamide), the
immunoconjugate was then radiolabeled with 99mTc. Hynic is an efﬁ-
cient bifunctional chelator for 99mTc used for labeling biomolecules ded-
icated tomolecular imaging. An advantage of theHYNIC system is that it
requires co-ligands to coordinate the unbound sites on the Tc, and by
using various co-ligands such as tricine, ethylenediaminediacetic acid
(EDDA) and glucoheptonate allowing the researcher to adjust the polar-
ity of themolecule. It is also known that in vitro and in vivo properties of
peptides and antibodies could be greatly affected by a co-ligand. The
tricine formulation was already found unstable in vitro under diluted
condition, in contrast Ono and co-workers have demonstrated that
plasma proteins can stabilize Tc-99 m labeled hynic conjugated Fab
fragment when tricine is used as co-ligand [23]. [99mTc][Tc(HYNIC)]
radiolabeled to monoclonal antibody RAM.1 showed no decrease of im-
munoreactivity after radiolabeling. In addition, the targeted RAM.1 was
still able to accumulate in the thrombi, generated in mouse model of
acute thrombosis inducedby exposure of the endotheliumof the carotid
artery to FeCl3. The visualization of the thrombus using RAM.1 was not
due to its trapping in the thrombus but to its platelet afﬁnity. Indeed,
after injection of a large amount of non-speciﬁc antibody during the
thrombus formation, RAM.1 could still label the thrombus injection,
30min after its induction. This demonstrates the very good binding af-
ﬁnity and retention of speciﬁcity of RAM.1. The radiolabeled RAM.1was
mainly in the spleen 90 min after injection. This result was expected
since 1/3 of the plateletmass is sequestrated in this organ under normal
physiological conditions.
The main factors ensuring the success of rapid imaging of thrombi
relies in the ability to deliver the tracer to the thrombus with high
thrombus afﬁnity and speciﬁcity, and to select the radiotracer that can
Fig. 3. Biodistribution of [99mTc][Tc(HYNIC)-RAM.1]. Radioactivity uptake in the different organs 90min and 240 min post injection wasmeasured using a gamma counter and expressed
as percentage injected dose per gram of tissue (n=5 for each group).
25A. Ouadi et al. / Nuclear Medicine and Biology 61 (2018) 21–27ﬁnd the highest concentration of binding sites exposed on the thrombus
with a rapid clearance of blood andmuscle background. It is known that
large size radiolabeled monoclonal antibodies persist in the circulation
for a prolonged period of time causing a high background signal making
targeted uptake difﬁcult to distinguish. Despite relatively slowclearance
from the blood, around 10 h (data not shown) which is an intrinsic
problem in the use of monoclonal antibodies to develop molecular
probes, [99mTc][Tc(HYNIC)-RAM.1] has a great potential as in vivomo-
lecular imaging probes. Results from our studies clearly demonstrated
the ability of this radioimmunoconjugate for detecting thrombi from
10min post injection with an exceptional thrombi uptake.Fig. 4. Small-animal SPECT images of an in vivomodel of mouse carotid artery thrombosis 90m
the radiolabeled RAM.1 at the site of injury in all injected mice (n= 5).Similar approaches with probes showing signiﬁcant uptake in fresh
thrombi without signal enhancement when used to image old thrombi
have failed in the past due to the short time-window for clinical applica-
tion. Main limitations of probes previously investigated in the clinic
were low target-to- background ratios, slow clearance and inability to
distinguish acute versus chronic disease [24]. For example,
99mTechnetium labeled peptide apcitide (99mTc-Acutect®), a syn-
thetic RGD-mimicking polypeptide, which binds to glycoprotein IIb/
IIIa receptors on activated platelets was approved for clinical use in
1998 for detection of acute deep vein thrombosis but was later aban-
doned [25].in after injection of the radiotracer. Analysis of the SPECT/CT images revealed an uptake of
Fig. 5. Ratio between the radioactivity measured in the injury site with FeCl3 or 0.9% NaCl over that in the adjacent surrounding (n= 5). Using FeCl3, the median ratio between the
thrombus and the background was 12.4 as compared to 1.0 when using 0.9% NaCl *Signiﬁcance (p b 0.05).
DAPI IgG-A488 BF Composite
Zoom
DAPI RAM.1-A488 BF Composite
Fig. 6. Visualization of a thrombus within the carotid artery after FeCl3 injury. Fluorescence (left panels) and bright ﬁeld microscopic images (right panels) of the thrombus formed after
FeCl3-induced carotid injury inmice (n= 5) that underwent CT/SPECT imaging. Platelets forming a thrombuswere detectedwith RAM.1 coupled to Alexa-488 and endothelial cellswithin
the vessel wall were detected with DAPI staining. These images conﬁrm the presence of a thrombus at a site of FeCl3-injury. These images are representative of three independent
experiments.
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27A. Ouadi et al. / Nuclear Medicine and Biology 61 (2018) 21–27Despite a slow blood clearance and high accumulation in non-target
tissues (mainly spleen, lungs, liver) radiolabeled RAM.1 represents a
very useful tool to detect and image thrombus since the ratio between
the signal recorded on the thrombus and the background (or contralat-
eral signal) is important: 12.4. In other cases this ratio is between 2 and
6 [10,12,26,27]. Analysis of whole body SPECT images showed that the
thrombosis area contain the highest uptake per mm3 (even superior
than the spleen).
Of note, this antibody which was developed in rats to bind mouse
GPIbβ, also cross-reacts with its human counterpart, and offers the se-
ducing opportunity to be tested in humans in future experiments.
5. Conclusion
We demonstrated that the radiolabeled RAM.1 after addition of
Hynic and 99mTc was still able to recognize platelets ex vivo. In vivo,
we described the high efﬁciency of radiolabeled RAM.1 to recognize
platelet thrombi. SPECT-CT sensitivity allowed the detection and the lo-
calization of the thrombus. Because of the relative low cost and high
sensitivity, these results encourage further study like the detection of
non-induced thrombus and further developments toward clinical appli-
cation. This is further supported by the fact that RAM.1 recognizes
human platelets.
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